Doctors' Personal Experience of Breast Cancer May Impact Care

Share this content:
Doctors' Personal Experience of Breast Cancer May Impact Care
Doctors' Personal Experience of Breast Cancer May Impact Care

WEDNESDAY, Dec. 6, 2017 (HealthDay News) -- Physicians who report a social network member with a poor breast cancer prognosis are more likely to recommend routine breast cancer screening for younger and older age groups, according to a research letter published online Dec. 4 in JAMA Internal Medicine.

Craig Evan Pollack, M.D., from the Johns Hopkins School of Medicine in Baltimore, and colleagues examined whether physician experiences with patients, friends, colleagues, and family members diagnosed with breast cancer correlated with their breast cancer screening recommendations. Data were included from a sample of 848 physicians.

The researchers found that of the social network members, 18.6 percent had poor prognosis, and more than half of these had not been diagnosed by screening. The likelihood of recommending screening for women aged 40 to 44 years and those aged 75 years or older was increased for physicians who reported at least one social network member with a poor prognosis who was not diagnosed by screening, compared to those who did not report a social network member in this category (probability for women aged 40 to 44 years: 92.7 versus 85.6 percent; for women ≥75 years: 84.0 versus 68.3 percent). There was no variation in this association by the type of social network member.

"Helping clinicians reflect on how their experiences influence their current screening patterns may be an important approach to improve adherence to revised breast cancer screening guidelines," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

Lab  Companion Tests Perform Similarly for Oncology Analytes

Lab + Companion Tests Perform Similarly for Oncology ...

Findings based on comparison of tests to diagnose oncology-related genetic variants

Ulixertinib Is Active in Patients With Advanced Solid Tumors

Ulixertinib Is Active in Patients With Advanced Solid ...

Responses occurred in patients with NRAS-, BRAF V600-, non-V600 BRAF-mutant solid tumors

Doctors Must Report on at Least 1 Patient, 1 Measure for MACRA

Doctors Must Report on at Least 1 Patient, ...

To avoid Medicare payment penalty in 2019, clinicians must report by Dec. 31, submit by Feb. 28

is free, fast, and customized just for you!

Already a member?

Sign In Now »